AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 137693 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A alone
Number of subjects: 0
Study 137693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 137693 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (135 mg daily) after 12 weeks
Number of subjects: 0
Study 31426247 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplastics (0.5 to 5 mm) quantified from sand samples taken from beaches
Number of subjects: 0
Study 31426247 — intervention group
Group type: COMPARATOR
Intervention: Beach location (inside versus outside the estuary)
Number of subjects: 0
Study 31426247 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfibers
Number of subjects: 0
Study 31426247 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration of microplastics in depositions of European shag and gulls
Number of subjects: 0
Study 28850388 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected painful stimuli
Number of subjects: 20
Study 28850388 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham stimuli
Number of subjects: 20
Study 28850388 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected painful stimuli
Number of subjects: 20
Study 28850388 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-painful stimuli
Number of subjects: 20
Study 28850388 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected pain (NRS)
Number of subjects: 20
Study 28850388 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected pain (NRS)
Number of subjects: 20
Study 26035253 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-639 (100 mg oral dose)
Number of subjects: 39
Study 26035253 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 39
Study 26035253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 23497778 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 1115
Study 23497778 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 1115
Study 23497778 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up IVUS
Number of subjects: 1115
Study 21692822 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Number of subjects: 155
Study 21692822 — intervention group
Group type: COMPARATOR
Intervention: Adefovir
Number of subjects: 155
Study 20045801 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg elemental zinc
Number of subjects: 60
Study 20045801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16421680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 micro.kg(‐1).h(‐1) for 10 min followed by 0.2 micro.kg(‐1).h(‐1) for 50 min)
Number of subjects: 40
Study 16421680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15077079 — intervention group
Group type: EXPERIMENTAL
Intervention: External loop recorders (ELRs)
Number of subjects: 78
Study 11734515 — intervention group
Group type: EXPERIMENTAL
Intervention: Short wavelength sensitive (SWS) cone mediated sensitivity measured by blue on yellow perimetry
Number of subjects: 126
Study 11734515 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of soft drusen
Number of subjects: 126
Study 11734515 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eyes with sight threatening complications of age related macular degeneration (AMD)
Number of subjects: 126
Study 11734515 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal hyperpigmentation
Number of subjects: 126
Study 9113633 — intervention group
Group type: EXPERIMENTAL
Intervention: High-AA diet (1.5 g/d of additional 20:4n‐6)
Number of subjects: 10
Study 9113633 — intervention group
Group type: COMPARATOR
Intervention: Low-AA diet (210 mg/d of 20:4n‐6)
Number of subjects: 10
Study 8187319 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I administered subcutaneously in a dose of 40 micrograms/kg body weight
Number of subjects: 9
Study 3048523 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exposure in vivo instructed by a psychiatrist
Number of subjects: 84
Study 3048523 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exposure in vivo instructed by a computer
Number of subjects: 84
Study 3048523 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exposure in vivo instructed by a book
Number of subjects: 84
Study 31148412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg administered after a high-fat and high-calorie meal
Number of subjects: 204
Study 31148412 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg administered in fasting state
Number of subjects: 204
Study 31148412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg administered in fed state
Number of subjects: 204
Study 31148412 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of pharmacokinetic characteristics between male and female subjects
Number of subjects: 204
Study 31764147 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (muscular ankle strengthening and plantar sensory stimulation)
Number of subjects: 66
Study 31764147 — intervention group
Group type: COMPARATOR
Intervention: Control group (foot care instructions only)
Number of subjects: 66
Study 28782664 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-hold maneuver training
Number of subjects: 15
Study 25420897 — intervention group
Group type: EXPERIMENTAL
Intervention: Racotumomab-alum vaccine
Number of subjects: 0
Study 25420897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23337183 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help Acceptance and Commitment Therapy (ACT) with e-mail support
Number of subjects: 250
Study 23337183 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 250
Study 21554439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (community pharmacy-led management)
Number of subjects: 1441
Study 21554439 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1441
Study 21554439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (females)
Number of subjects: 1441
Study 19654233 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-GH (1 mg for 3 weeks, then 2 mg for 3 weeks)
Number of subjects: 105
Study 19654233 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-GH (3 mg for 3 weeks, then 6 mg for 3 weeks)
Number of subjects: 105
Study 19654233 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-GH (4 mg for 3 weeks, then 8 mg for 3 weeks)
Number of subjects: 105
Study 19654233 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-GH (4 mg for 6 weeks)
Number of subjects: 105
Study 19654233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 16966367 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m(2) twice daily days 1-14) plus Docetaxel (75 mg/m(2) day 1)
Number of subjects: 0
Study 16966367 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced doses of Capecitabine (950 mg/m(2)) and Docetaxel (55 mg/m(2))
Number of subjects: 0
Study 16966367 — intervention group
Group type: COMPARATOR
Intervention: Full doses of Capecitabine and Docetaxel
Number of subjects: 0
Study 16145909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (group W)
Number of subjects: 20
Study 16145909 — intervention group
Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 20
Study 10670523 — intervention group
Group type: COMPARATOR
Intervention: Electromotive drug administration of the 3-drug association orgotein-dexamethasone-lidocaine (study 1)
Number of subjects: 65
Study 10670523 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromotive drug administration of the 2-drug combination verapamil-dexamethasone (study 2)
Number of subjects: 65
Study 9487787 — intervention group
Group type: COMPARATOR
Intervention: PCA with piritramide (PCA-control)
Number of subjects: 45
Study 9487787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal blocks (ICB) with 5 ml bupivacaine 0.5%
Number of subjects: 45
Study 9487787 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural analgesia (IPA) with 20 ml bupivacaine 0.25%
Number of subjects: 45
Study 9487787 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (PCA, ICB, IPA)
Number of subjects: 45
Study 8454016 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap task
Number of subjects: 43
Study 8454016 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap task
Number of subjects: 43
Study 3544688 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 50
Study 3544688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29511130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1578
Study 29511130 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1578
Study 29469337 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (30 mg/(kg·d) for 2 days each year for three consecutive years)
Number of subjects: 60
Study 29469337 — intervention group
Group type: COMPARATOR
Intervention: Conventional liver protection therapy and symptomatic treatment
Number of subjects: 60
Study 25516314 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid milk supplementation
Number of subjects: 3526
Study 25516314 — intervention group
Group type: COMPARATOR
Intervention: Control group (no liquid milk)
Number of subjects: 3526
Study 22781890 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cryopreserved platelet transfusion
Number of subjects: 40
Study 22781890 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic fresh platelet transfusion (Control)
Number of subjects: 40
Study 20140619 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term therapy (4 days)
Number of subjects: 106
Study 20140619 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (7 days)
Number of subjects: 106
Study 20140619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 106
Study 18725489 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 626
Study 18725489 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 626
Study 15979218 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (intervention group)
Number of subjects: 20
Study 15979218 — intervention group
Group type: COMPARATOR
Intervention: Young adults (control group)
Number of subjects: 20
Study 12739705 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg o.d.
Number of subjects: 440
Study 12739705 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.i.d.
Number of subjects: 440
Study 12739705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 10561618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic (15S)-15-methyl-prostaglandin F2alpha (2.5 mg)
Number of subjects: 51
Study 10561618 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal misoprostol (200 microg, two doses at 12-hour intervals)
Number of subjects: 51
Study 10561618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic (15S)-15-methyl-prostaglandin F2alpha
Number of subjects: 51
Study 10561618 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal misoprostol
Number of subjects: 51
Study 8701900 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 52
Study 8701900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 1863049 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0
Study 1863049 — intervention group
Group type: COMPARATOR
Intervention: Halothane and trichlorethylene
Number of subjects: 0
Study 6229096 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg depot medroxyprogesterone acetate (DMPA) intramuscularly
Number of subjects: 30
Study 6229096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30395789 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed instruction group
Number of subjects: 144
Study 30395789 — intervention group
Group type: COMPARATOR
Intervention: Accuracy instruction group
Number of subjects: 144
Study 28104188 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal multiple micronutrients (MMN) supplementation
Number of subjects: 2879
Study 28104188 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioenvironmental determinants
Number of subjects: 2879
Study 28104188 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical determinants
Number of subjects: 2879
Study 26775606 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (100 or 200 mg, multiple doses; 25, 100, or 200 mg every 4 weeks)
Number of subjects: 38
Study 26775606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 24807628 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month group-based circuit exercise program combined with a 3-h educational session
Number of subjects: 89
Study 24807628 — intervention group
Group type: COMPARATOR
Intervention: Usual activities
Number of subjects: 89
Study 22421748 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus type 5 (Ad5) vector‐based vaccine
Number of subjects: 1764
Study 22421748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1764
Study 19388125 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar bowing of the flexor retinaculum (PBFR) measured on MRI in CTS patients
Number of subjects: 48
Study 19388125 — intervention group
Group type: COMPARATOR
Intervention: Control group (21 healthy women with no symptoms of CTS)
Number of subjects: 48
Study 17950142 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 200
Study 17950142 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 200
Study 15903383 — intervention group
Group type: EXPERIMENTAL
Intervention: Full range-of-motion training (Group 1: n = 13)
Number of subjects: 29
Study 15903383 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial range-of-motion training (Group 2: n = 8)
Number of subjects: 29
Study 15903383 — intervention group
Group type: COMPARATOR
Intervention: Mixed range-of-motion training (Group 3: n = 8)
Number of subjects: 29
Study 12909491 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) agonist treatment for 3 months before laparoscopic surgery
Number of subjects: 22
Study 12909491 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy for ovarian endometriomas
Number of subjects: 22
Study 12909491 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriotic stromal cells obtained from patients with GnRH agonist treatment
Number of subjects: 22
Study 12909491 — intervention group
Group type: COMPARATOR
Intervention: Patients without endometriomas
Number of subjects: 22
Study 10319770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil plus propofol titrated to electroencephalographic burst suppression
Number of subjects: 225
Study 10319770 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (control group)
Number of subjects: 225
Study 9139008 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-sympathomimetics (exposed group)
Number of subjects: 78
Study 9139008 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed to beta-mimetics (control group)
Number of subjects: 78
Study 2007285 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue lens (high water content ionic lens)
Number of subjects: 15
Study 2007285 — intervention group
Group type: COMPARATOR
Intervention: SeeQuence lens (low water content non-ionic lens)
Number of subjects: 15
Study 2007285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lenses
Number of subjects: 15
Study 2007285 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue lens
Number of subjects: 15
Study 2007285 — intervention group
Group type: COMPARATOR
Intervention: SeeQuence lens
Number of subjects: 15
Study 6290132 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g guar gum
Number of subjects: 0
Study 6290132 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g guar gum with 25 g D-xylose
Number of subjects: 0
Study 6290132 — intervention group
Group type: COMPARATOR
Intervention: Control study without guar
Number of subjects: 0
Study 30306240 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing Region A (0°‐60°)
Number of subjects: 15
Study 30306240 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing Region A + B (0°‐120°)
Number of subjects: 15
Study 30306240 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing Region B (60°‐120°)
Number of subjects: 15
Study 30306240 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing Region A + C (0°‐60°, 120°‐180°)
Number of subjects: 15
Study 28978356 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS Anxiety
Number of subjects: 6659
Study 28978356 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS Depression
Number of subjects: 6659
Study 25631909 — intervention group
Group type: EXPERIMENTAL
Intervention: PtCr-EES
Number of subjects: 500
Study 25631909 — intervention group
Group type: COMPARATOR
Intervention: PES
Number of subjects: 500
Study 23435021 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) - Daily conjugated equine estrogens (0.625 mg) and medroxyprogesterone acetate (2.5 mg; EPT) or conjugated equine estrogens (0.625 mg; ET)
Number of subjects: 27
Study 23435021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 22013792 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaochuangao Acupoint Paste (XAP)
Number of subjects: 142
Study 22013792 — intervention group
Group type: COMPARATOR
Intervention: Placebo paste
Number of subjects: 142
Study 19744406 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 23
Study 16777915 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 3916
Study 16777915 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 3916
Study 15743112 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioctic acid at an oral dosage of 800 mg/day for 4 months
Number of subjects: 0
Study 15743112 — intervention group
Group type: COMPARATOR
Intervention: Dietary supplementation with antioxidant micronutrients
Number of subjects: 0
Study 11064772 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefuroxime axetil for 10 days
Number of subjects: 86
Study 11064772 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular benzathine penicillin (one dose)
Number of subjects: 86
Study 9315571 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal unsatisfactory outcome end point (composite end point)
Number of subjects: 576
Study 9315571 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal unsatisfactory outcome end point
Number of subjects: 576
Study 9315571 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset severe congestive heart failure/shock
Number of subjects: 576
Study 9315571 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction <40%
Number of subjects: 576
Study 9315571 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent myocardial infarction
Number of subjects: 576
Study 9315571 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI flow grade <2 at 90 minutes
Number of subjects: 576
Study 8364872 — intervention group
Group type: EXPERIMENTAL
Intervention: LC9018 combined with radiation therapy
Number of subjects: 228
Study 8364872 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 228
Study 3490334 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 47
Study 3490334 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 47
Study 31561326 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL-SJ
Number of subjects: 22
Study 31561326 — intervention group
Group type: COMPARATOR
Intervention: CPT
Number of subjects: 22
Study 28541742 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm communication style
Number of subjects: 89
Study 28541742 — intervention group
Group type: COMPARATOR
Intervention: Neutral communication style
Number of subjects: 89
Study 28541742 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced information about the placebo training program
Number of subjects: 89
Study 28541742 — intervention group
Group type: COMPARATOR
Intervention: Basic information about the placebo training program
Number of subjects: 89
Study 27090804 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LPS)
Number of subjects: 662
Study 27090804 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 662
Study 25518099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness programme offered by Fitness World
Number of subjects: 58
Study 25518099 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobics group sessions and gym sessions (for men)
Number of subjects: 58
Study 25518099 — intervention group
Group type: EXPERIMENTAL
Intervention: Any activities (for women)
Number of subjects: 58
Study 25518099 — intervention group
Group type: EXPERIMENTAL
Intervention: Time preference for fitness activities
Number of subjects: 58
Study 22172305 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 1414
Study 22172305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1414
Study 20122682 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Limberg flap (MLF) transposition
Number of subjects: 145
Study 20122682 — intervention group
Group type: COMPARATOR
Intervention: Karydakis flap reconstruction
Number of subjects: 145
Study 18718738 — intervention group
Group type: COMPARATOR
Intervention: Endoscope
Number of subjects: 70
Study 18718738 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscope
Number of subjects: 70
Study 16205946 — intervention group
Group type: EXPERIMENTAL
Intervention: epirubicin (median cumulative dose: 450 mg/m2)
Number of subjects: 172
Study 16205946 — intervention group
Group type: COMPARATOR
Intervention: doxorubicin (median cumulative dose: 240 mg/m2)
Number of subjects: 172
Study 16205946 — intervention group
Group type: EXPERIMENTAL
Intervention: epirubicin and doxorubicin
Number of subjects: 172
Study 12838282 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 62